Your browser doesn't support javascript.
loading
SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation.
Zaman, Tariq; Helbig, Katherine L; Clatot, Jérôme; Thompson, Christopher H; Kang, Seok Kyu; Stouffs, Katrien; Jansen, Anna E; Verstraete, Lieve; Jacquinet, Adeline; Parrini, Elena; Guerrini, Renzo; Fujiwara, Yuh; Miyatake, Satoko; Ben-Zeev, Bruria; Bassan, Haim; Reish, Orit; Marom, Daphna; Hauser, Natalie; Vu, Thuy-Anh; Ackermann, Sally; Spencer, Careni E; Lippa, Natalie; Srinivasan, Shraddha; Charzewska, Agnieszka; Hoffman-Zacharska, Dorota; Fitzpatrick, David; Harrison, Victoria; Vasudevan, Pradeep; Joss, Shelagh; Pilz, Daniela T; Fawcett, Katherine A; Helbig, Ingo; Matsumoto, Naomichi; Kearney, Jennifer A; Fry, Andrew E; Goldberg, Ethan M.
Affiliation
  • Zaman T; Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Helbig KL; Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Clatot J; Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Thompson CH; Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Kang SK; Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Stouffs K; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Jansen AE; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Verstraete L; Center for Medical Genetics/Research Center for Reproduction and Genetics, University Hospital Brussels, Free University of Brussels, Brussels, Belgium.
  • Jacquinet A; Pediatric Neurology Unit, Department of Pediatrics, University Hospital Brussels, Brussels, Belgium.
  • Parrini E; Neurogenetics Research Group, Free University of Brussels, Brussels, Belgium.
  • Guerrini R; Child Neurology, Heilig Hart Hospital Lier, Lier, Belgium.
  • Fujiwara Y; Human Genetics Service, Sart Tilman University Hospital Center, Liege, Belgium.
  • Miyatake S; Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, Department of Neuroscience, A. Meyer Children's Hospital, University of Florence, Florence, Italy.
  • Ben-Zeev B; Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, Department of Neuroscience, A. Meyer Children's Hospital, University of Florence, Florence, Italy.
  • Bassan H; Department of Pediatrics, Yokohama City University Medical Center, Yokohama, Japan.
  • Reish O; Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Marom D; Pediatric Neurology Unit, Edmond and Lili Safra Children's Hospital, Haim Sheba Medical Center, Ramat Gan, Israel.
  • Hauser N; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Vu TA; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ackermann S; Pediatric Neurology & Development Center, Shamir Medical Center (Assaf Harofe), Zerifin, Israel.
  • Spencer CE; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Lippa N; Genetics Institute, Shamir Medical Center (Assaf Harofe) Zerifin, Zerifin, Israel.
  • Srinivasan S; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Charzewska A; Genetics Institute, Shamir Medical Center (Assaf Harofe) Zerifin, Zerifin, Israel.
  • Hoffman-Zacharska D; Inova Translational Medicine Institute, Inova Health System, Fairfax, Virginia, USA.
  • Fitzpatrick D; Department of Pediatric Neurology, Children's National Medical Center, Washington, District of Columbia, and Pediatric Specialists of Virginia, Fairfax, Virginia, USA.
  • Harrison V; Division of Paediatric Neurology, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.
  • Vasudevan P; Division of Human Genetics, Department of Medicine, University of Cape Town, South Africa and Groote Schuur Hospital, Cape Town, South Africa.
  • Joss S; Institute for Genomic Medicine, Columbia University Medical Center, New York, New York, USA.
  • Pilz DT; Department of Neurology, Columbia University Medical Center, New York, New York, USA.
  • Fawcett KA; Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland.
  • Helbig I; Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland.
  • Matsumoto N; Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Kearney JA; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kingdom.
  • Fry AE; Department of Clinical Genetics, University Hospitals Leicester National Health Service Trust, Leicester, United Kingdom.
  • Goldberg EM; West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Ann Neurol ; 88(2): 348-362, 2020 08.
Article in En | MEDLINE | ID: mdl-32515017
ABSTRACT

OBJECTIVE:

Pathogenic variants in SCN3A, encoding the voltage-gated sodium channel subunit Nav1.3, cause severe childhood onset epilepsy and malformation of cortical development. Here, we define the spectrum of clinical, genetic, and neuroimaging features of SCN3A-related neurodevelopmental disorder.

METHODS:

Patients were ascertained via an international collaborative network. We compared sodium channels containing wild-type versus variant Nav1.3 subunits coexpressed with ß1 and ß2 subunits using whole-cell voltage clamp electrophysiological recordings in a heterologous mammalian system (HEK-293T cells).

RESULTS:

Of 22 patients with pathogenic SCN3A variants, most had treatment-resistant epilepsy beginning in the first year of life (16/21, 76%; median onset, 2 weeks), with severe or profound developmental delay (15/20, 75%). Many, but not all (15/19, 79%), exhibited malformations of cortical development. Pathogenic variants clustered in transmembrane segments 4 to 6 of domains II to IV. Most pathogenic missense variants tested (10/11, 91%) displayed gain of channel function, with increased persistent current and/or a leftward shift in the voltage dependence of activation, and all variants associated with malformation of cortical development exhibited gain of channel function. One variant (p.Ile1468Arg) exhibited mixed effects, with gain and partial loss of function. Two variants demonstrated loss of channel function.

INTERPRETATION:

Our study defines SCN3A-related neurodevelopmental disorder along a spectrum of severity, but typically including epilepsy and severe or profound developmental delay/intellectual disability. Malformations of cortical development are a characteristic feature of this unusual channelopathy syndrome, present in >75% of affected individuals. Gain of function at the channel level in developing neurons is likely an important mechanism of disease pathogenesis. ANN NEUROL 2020;88348-362.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Sodium Channels / Epilepsy / NAV1.3 Voltage-Gated Sodium Channel / Neurodevelopmental Disorders Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Ann Neurol Year: 2020 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Sodium Channels / Epilepsy / NAV1.3 Voltage-Gated Sodium Channel / Neurodevelopmental Disorders Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Ann Neurol Year: 2020 Document type: Article Affiliation country: Estados Unidos